Merit Medical Systems/$MMSI
1D1W1MYTD1Y5YMAX
Capital at risk
About Merit Medical Systems
Merit Medical Systems Inc is a medical equipment company that develops and manufactures products for interventional cardiology, radiology, and endoscopy procedures. The firm reports two segments which are Cardiovascular and Endoscopy. The majority of the revenue is earned from the Cardiovascular segment which consists of cardiology and radiology medical device products that assist in diagnosing and treating coronary artery disease, peripheral vascular disease, and other non-vascular diseases and includes embolotherapeutic, cardiac rhythm management, electrophysiology, critical care, and interventional oncology and spine devices.
- Ticker
- $MMSI
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 7,500
- Headquarters
- South Jordan, United States
- Website
- www.merit.com
MMSI Metrics
BasicAdvanced
$5.1B
35.12
$2.43
0.49
-
Price and volume
Market cap
$5.1B
Beta
0.49
52-week high
$94.75
52-week low
$59.74
Average daily volume
718K
Financial strength
Current ratio
4.198
Quick ratio
2.641
Long term debt to equity
0.482
Total debt to equity
0.488
Interest coverage (TTM)
6.83%
Profitability
EBITDA (TTM)
341.477
Gross margin (TTM)
49.51%
Net profit margin (TTM)
9.22%
Operating margin (TTM)
13.75%
Effective tax rate (TTM)
25.15%
Revenue per employee (TTM)
$210,000
Management effectiveness
Return on assets (TTM)
4.92%
Return on equity (TTM)
9.19%
Valuation
Price to earnings (TTM)
35.123
Price to revenue (TTM)
3.214
Price to book
3.03
Price to tangible book (TTM)
9.65
Price to free cash flow (TTM)
25.405
Free cash flow yield (TTM)
3.94%
Free cash flow per share (TTM)
3.36
Growth
Revenue change (TTM)
10.19%
Earnings per share change (TTM)
23.23%
3-year revenue growth (CAGR)
9.63%
10-year revenue growth (CAGR)
10.93%
3-year earnings per share growth (CAGR)
16.47%
10-year earnings per share growth (CAGR)
16.90%
What the Analysts think about MMSI
Analyst ratings (Buy, Hold, Sell) for Merit Medical Systems stock.
Analyst projections of the future price of Merit Medical Systems stock.
Bulls say / Bears say
Merit delivered second quarter revenue of $418.8 million, up 9.5% year-over-year with GAAP operating margin expanding to 14.4% from 12.3% and non-GAAP EPS rising 18%, underscoring robust top-line growth and improving profitability (SEC Form 8-K).
Management increased full-year 2026 revenue guidance to $1.612–$1.634 billion and non-GAAP EPS guidance to $4.01–$4.15 after Q2 results beat expectations, signaling confidence in sustained growth and margin improvement (SEC Form 8-K).
The April 1 acquisition of View Point Medical expands Merit’s therapeutic oncology portfolio with the OneMark® system, projected to add $2 million–$4 million in 2026 revenue at ~70% gross margins, diversifying its offering into high-growth markets (GlobeNewswire).
Merit faces execution and integration risks from recent acquisitions (View Point Medical, C2 CryoBalloon, Biolife) and the strategic divestiture of the DualCap® product line, which could result in heightened operational expenses and distract management, as noted in its Q2 risk disclosures (SEC Form 10-Q).
Free cash flow generation declined by 14% year-to-date, with Q2 free cash flow of $76.6 million down from the prior year period, potentially limiting funding for strategic initiatives (SEC Form 8-K).
As of March 31, 2026, Merit’s cash and cash equivalents of $488.1 million against total debt of $747.5 million implies a net leverage ratio exceeding 1x, which may constrain financial flexibility amid rising interest rates (Q1 2026 Press Release).
Data summarised monthly by Lightyear AI. Last updated on 4 Sept 2026.
MMSI Financial Performance
Revenues and expenses
MMSI Earnings Performance
Company profitability
Upcoming events
No upcoming events
MMSI News
AllArticlesVideos
Funds containing MMSI
AllUSDGBPEUR
Fund name | Fund size | $MMSI weighting |
|---|---|---|
iShares S&P SmallCap 600$IDP6 | $3.2B | 0.29% |
iShares S&P Small Cap 600£ISP6 | £2.4B | 0.29% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.17% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | €2.8B | 0.13% |
iShares MSCI USA Small Cap CTB Enhanced ESG£CUS1 | £2.4B | 0.13% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.